Full Press Release Details
HELIUS MEDICAL TECHNOLOGIES AND U.S. ARMY EXTEND SOLE SOURCE
FOR THE PONS DEVICE TESTING AND DEVELOPMENT
(Newtown, PA) November 21, 2016 - Helius Medical
Technologies, Inc. (TSX: HSM) (OTCQB: HSDT) ( Helius or the Company )
announced that NeuroHabilitation Corporation ( NHC ), a division of Helius,
successfully executed an amendment to the sole source cost sharing contract
entered into with the U.S. Army Medical Research and Materiel Command (USAMRMC).
The contract is extended to December 31, 2017 and allows Helius to
include additional study sites for the clinical trial investigating the safety
and effectiveness of the Portable Neuromodulation Stimulator (PoNS ) for
the treatment of chronic balance deficits in subjects with mild to moderate
traumatic brain injury (mTBI).
Extending this contract reflects a continued commitment from
the USAMRMC and Helius to
address the large unmet clinical need represented by both civilian and military patients suffering from
chronic symptoms of traumatic brain injury,
said Helius CEO, Phil Deschamps.
The Portable Neuromodulation Stimulator (PoNS) device is an
investigational medical device being studied for the treatment of neurological
symptoms caused by disease or trauma. The PoNS is currently being studied in the
United States and Canada for the treatment of chronic balance deficits in
The PoNS device is a non-invasive means for delivering
neurostimulation through the tongue. Researchers believe that use of the tongue
as a gateway to the brain may be one of the most natural, non-invasive and
direct ways to stimulate the brain. The tongue is anatomically unique, being
richly innervated by thousands of nerve fibers and interconnected to the
brainstem by two major cranial nerves.
About Helius Medical Technologies (HMT)
Helius Medical Technologies is a medical technology company
focused on neurological wellness. HMT seeks to develop, license and acquire
unique and non-invasive platform technologies that amplify the brain s ability
to heal itself. HMT intends to file for U.S. Food and Drug Administration
clearance for the PoNS device. For more information, please visit
The contents of this website are not, and should be deemed to
be, incorporated by reference herein.
The Canadian Securities Exchange has not reviewed and does
not accept responsibility for the adequacy or accuracy of the content of this
Cautionary Disclaimer Statement:
This press release contains forward-looking statements relating
to the results of the Company s registrational clinical trial, FDA submission
process, planned future commercial distribution, and other statements that are
not historical facts. Forward-looking statements are often identified by terms
such as will , may , should , anticipate , expects and similar
expressions. All statements other than statements of historical fact, included
in this release are forward-looking statements that involve risks and
uncertainties. There can be no assurance that such statements will prove to be
accurate and actual results and future events could differ materially from those
anticipated in such statements. Important factors that could cause actual
results to differ materially from the Company s expectations include the failure
to satisfy the conditions of the Securities and Exchange Commission and the
Canadian Securities Exchange, the success of the Company s business plan,
availability of funds, government regulations, operating costs, the Company s
ability to achieve revenues and other risks detailed from time to time in the
filings made by the Company with its securities regulators.
The reader is cautioned that assumptions used in the
preparation of any forward-looking information may prove to be incorrect. Events
or circumstances may cause actual results to differ materially from those
predicted, as a result of numerous known and unknown risks, uncertainties, and
other factors, many of which are beyond the control of the Company. Many factors
may cause the Company s actual results to differ materially from any
forward-looking statement. The reader is cautioned not to place undue reliance
on any forward-looking information. Such information, although considered
reasonable by management at the time of preparation, may prove to be incorrect
and actual results may differ materially from those anticipated. Forward-looking
statements contained in this press release are expressly qualified by this
cautionary statement. The forward-looking statements contained in this press
release are made as of the date of this press release and the Company undertakes
no obligation to update or revise publicly this press release to reflect events
or circumstances after the date hereof, except as required by applicable law.